Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis announces deal to license programme

Novartis announces deal to license programme

29th December 2008

Novartis has announced an agreement that will see it gaining the rights to license the Cytomegalovirus vaccine programme.

The deal with AlphaVax for $20 million (13.6 million pounds) will see the company responsible for registration and marketing around the world.

In turn, AlphaVax will be able to receive milestones and royalties gained from the collaboration.

Dr Andrin Oswald, chief executive officer of Novartis Vaccines and Diagnostics, said: “We are happy to gain access to a promising vaccine candidate for the prevention of cytomegalovirus infections, which are particularly problematic during pregnancy as they can cause permanent disability in newborns.”

There are currently no other jabs available for the treatment of Cytomegalovirus, however it is hoped the vaccine will enter clinical trials in 2009.

It is the current cause of 700 fatalities and 17,500 cases of severe disability per year, Novartis states.

Other vaccines in Novartis’ pipeline include injections for the prevention of Helicobacter pylori infections, a cause of gastric cancer.

Currently employing almost 100,000 people, the company was formed in 1996 as a result of the merger of two organisations.

In 2007, Novartis increased its research and development investments to $6.4 billion and, in 2008, was ranked second in Fortune magazine’s World’s Most Admired Companies study.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.